EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of YKL-40 in Alzheimer’s disease pathology and drug targeting

Yaru Sha, Hong Fu, Kun Lu, Guohui Wang, Yubing Wang

PeerJ · 08.06.2026 · 14 · e21361

DOI: 10.7717/peerj.21361 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PeerJ, online erschienen am 08.06.2026. Verfasst von Yaru Sha und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Shandong Second Medical University, Weifang, Shandong, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Chitinase-3-Like Protein 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Shandong Provincial Natural Science Foundation, Shandong Provincial Medical and Health Science and Technology Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques, hyperphosphorylated tau tangles, and significant neuronal loss. Recent studies have implicated YKL-40, a glycoprotein commonly associated with inflammation and neural apoptosis, in the pathogenesis of AD.

Methods

We conducted extensive searches across major scientific databases, including PubMed, Web of Science, and Embase. We selected peer-reviewed articles, review articles, and clinical studies focusing on YKL-40 in AD.

Results

This review comprehensively analyses the multifaceted role of YKL-40 in AD, covering its cellular localization, biomarker associations, and pathological mechanisms. We also summarize the mechanistic pathways by which YKL-40 contributes to disease progression, highlighting its role in neuroinflammation, neural apoptosis, and disruption of the circadian regulation of immune responses. Moreover, the development of drugs that target YKL-40, such as humanized anti-YKL-40 antibodies and small molecules, offers promising strategies for blocking AD progression.

Conclusion

This review highlights the potential of YKL-40 as a novel drug target and its implications for enhancing diagnostic precision and treatment strategies in combating Alzheimer’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseChitinase-3-Like Protein 1HumansAnimalsBiomarkersApoptosisDisease Progression

Stichwörter der Autor:innen

Alzheimer’s diseaseCHI3L1Drug targetsNeuroinflammationYKL-40

Substanzen

Chitinase-3-Like Protein 1CHI3L1 protein, humanBiomarkers

Autor:innen und Institutionen

  • School of Life Science and Technology, Shandong Second Medical University, Weifang, Shandong, China.
  • Translational Medical Center, Weifang No.2 People's Hospital, Weifang, Shandong, China.

Förderung

  • The Shandong Provincial Natural Science Foundation
  • Shandong Provincial Medical and Health Science and Technology Development Program

Zitieren

APA

Sha, Y., Fu, H., Lu, K., Wang, G., & Wang, Y. (2026). The role of YKL-40 in Alzheimer’s disease pathology and drug targeting. PeerJ, 14, e21361. https://doi.org/10.7717/peerj.21361

Vancouver

Sha Y, Fu H, Lu K, Wang G, Wang Y. The role of YKL-40 in Alzheimer’s disease pathology and drug targeting. PeerJ. 2026;14:e21361. doi:10.7717/peerj.21361

BibTeX
@article{Sha2026,
  author = {Sha, Yaru and Fu, Hong and Lu, Kun and Wang, Guohui and Wang, Yubing},
  title = {The role of YKL-40 in Alzheimer’s disease pathology and drug targeting},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21361},
  doi = {10.7717/peerj.21361}
}
Kostenlos starten →